Kornimate/medical-research-clean huggingface dataset:
tace-haic plus lenvatinib for patients with unresectable hcc: an open-label, single-arm, phase 2 trial

Conditions: Hepatocellular Carcinoma; Transarterial Chemoembolization

Summary: hepatocellular carcinoma (hcc) is one of the most commonly malignant tumors around the world. hepatic resection or liver transplantation is the radical method to cure the disease. however, due to multiple tumors or poor hepatic function reserve in cirrhosis, surgical treatment is suitable for early-stage and well reserved liver function patients. therefore, in clinical practice, transarterial chemoembolization (tace) is a preferential and standard treatment of unresectable hcc. tace has been proved to provide outstanding efficacy for treating advanced stage hcc patients. however, tace is associated with a high rate of treatment failure for advanced hcc patients. each trial opened the door to folfox-based system chemotherapy for advanced hcc patients. recently, investigators have showed that hepatic arterial infusion of folfox-based chemotherapy (haic) was safe and efficient for advanced hcc patients. the combination of tace with haic (tace-haic) was proved to increase the local doses of chemotherapeutic agents in the liver, reduce the viability of hcc cells and increase the hepatectomy rate in our previous study. levatinib is a new treatment and offers relative high overall response rate for advanced hcc, which was approved in china and japan. however, whether the combination of tace-haic and lenvatinib would increse tumor control for unresectable patients is still unknown. thus, this single arm, phase 2 study is designed to analyze the safety and efficacy tace-haic plus lenvatinib for patients with unresectalbe hcc.


Eligibility criteria:
inclusion criteria: * age 18-75 years 1. the diagnosis of hcc was based on the diagnostic criteria for hcc used by the european association for the study of the liver (easl) 2. unresectable disease, stage bclc b/c 3. no previous anti-hcc treatment 4. eastern co-operative group performance status 2 or less 5. liver function: child's a or b (score \< 7) exclusion criteria: * evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy 1. underlying serve cardiac or renal diseases 2. known or suspected allergy to the investigational agent or any agent given in association with this trial 3. patients ineligible for hepatic artery embolization
beneficial effects of pulmonary rehabilitation for idiopathic pulmonary fibrosis

Conditions: Idiopathic Pulmonary Fibrosis

Summary: idiopathic pulmonary fibrosis (ipf) is a devastating disease marked by progressive lung scarring leading to multiple life-altering sequelae. the over-arching goals of the principal investigator's research program are to more fully characterize these sequelae and to examine interventions that might improve them. the hypotheses of this particular study are that pulmonary rehabilitation (pr) is one such intervention, and that pr will improve the sequelae of dyspnea and impairments in functional capacity, cognition, mood and anxiety, fatigue, and quality of life (qol) in patients with ipf.

subjects will come to our center to be enrolled. baseline data collection (performance of a six-minute walk test and completion of questionnaires) and randomization to one of two groups--either rehab or wait--will take place at the same enrollment visit if time permits. subjects in either group will complete pulmonary rehabilitation, just at slightly different times, depending on which group they are randomized to. pulmonary rehabilitation is a program run by respiratory and/or physical therapists and other health professionals that involves exercise, education, and support with the goals to improve functional capacity, symptom management, and well-being. it will last 6-8 weeks, during which time, subjects will complete 18 approximately hour-long sessions. pulmonary rehabilitation may be completed at any local center that makes travel convenient. data collection visits will take place at national jewish health at baseline, eight weeks (without intervening pulmonary rehabilitation in the wait group), after completion of pulmonary rehabilitation (time varies, depending on the randomization group), and finally six months after completion of the pulmonary rehabilitation program.

Eligibility criteria:
inclusion criteria: * age \> 40 years * ipf * able to walk unassisted for balance * able to speak and understand english well enough to complete complex tasks with directions given in english exclusion criteria: * pulmonary fibrosis not due to ipf * coexisting comorbid conditions that would make exercise contraindicated

Keywords: idiopathic pulmonary fibrosis dyspnea functional capacity quality of life
pilot study of whole blood transfusion for trauma brain injury (tbi)

Conditions: Traumatic Brain Injury

Summary: our goal is to perform a pilot, single center study to evaluate the efficacy of whole blood (wb) in subjects with tbi, intracranial hemorrhage, and anemia compared to blood component therapy.

both whole blood and blood components are given as standard-of-care based on the blood products available. if enrolled in this study, patients will be randomized 1:1 to receive either whole blood or blood components first. they will continue to receive blood products based on their assigned group. if they require more blood product than is available, they will cross over to the other group so they can continue to receive the transfusions needed for treatment. the primary endpoint for this study would be improvement in coagulopathy pre and post intervention. additionally, we will evaluate hemorrhagic progression of the intracranial bleed (hpib), as measured by follow-up ct scan ordered over the first 24-hour post intervention (which is standard of care). the secondary outcomes parameters would include intracranial pressure measurements (if performed), survival to discharge, safety and tolerability of whole blood administration in the tbi population, coagulation parameters and total blood product use, glasgow coma scale (gcs) 24 hours post-injury, in-hospital mortality, and patient's discharge status (glasgow outcome score extended and disposition to home versus extended care facility). patients who decide to take part in the study, will have 26 ml of blood drawn (about 2 tablespoons) once before and once after blood transfusion for a total of 52 ml (about 4 tablespoons) of blood drawn, a ct scan at admission and at 24hour of blood transfusion, and information will be gathered from their medical record during their hospital stay.

Eligibility criteria:
inclusion criteria: * age 15 years and older * head ct with presence of intracranial bleeding * required transfusion of whole blood (wb) or red blood cells (rbc) exclusion criteria: * patients with non-survivable injuries (expected to die within 24-hours of injury) * fixed and dilated pupils * patients requiring a massive transfusion protocol activation * receipt of 2 units of wb or rbcs prior to enrollment * known prisoners * known pregnancy
pharmacokinetics of levodopa/carbidopa infusion with and without oral catechol-o-methyl transferase (comt) inhibitors

Conditions: Parkinson Disease

Summary: the purpose of this study is to determine whether oral intake of comt inhibitors affects the smooth plasma levodopa levels achieved by intestinal levodopa/carbidopa infusion in advanced parkinson's disease patients. the hypothesis is that comt inhibitors make plasma concentrations of levodopa more fluctuating.

the aim is to measure variability in plasma levodopa levels during the following three treatments: day 1: duodopa in individually optimised dose day 2: 80% of optimised duodopa dose + two tablets of entacapone at t=0 hours and at t= 6 hours day 3: 80% of optimised duodopa dose + two tablets of tolcapone at t=0 hours and at t= 6 hours plasma samples for determination of levodopa concentrations will be taken every 30 minutes during 8 hours. video recordings will be performed every 30 min during 8 hours, for later blinded assessments by 2-3 experts. sequences will be in randomised order. patient self-scores regarding mobility will be recorded, every 30 min during 8 hours.

Eligibility criteria:
inclusion criteria: * parkinson's disease * duodopa treatment ongoing * hoehn \& yahr stage 3-5 at worst exclusion criteria: * ongoing treatment with comt inhibitors * dementia * psychosis * treatment with typical neuroleptics * contraindications for entacapone or tolcapone

Keywords: levodopa/carbidopa infusion entacapone tolcapone efficacy pharmacokinetic pharmacodynamics
to determine the efficacy of a laser device for the treatment of hidradenitis suppurativa

Conditions: Hidradenitis Suppurativa

Summary: a research study to determine the efficacy of a 1320 nm laser device for the treatment of hidradenitis suppurativa.

hidradenitis suppurativa is a chronic, scarring disease. the treatments available for this condition are not very effective and work only for some patients. recently, a 1320nm laser device has been approved by the fda for the treatment of acne and facial rejuvenation. given the positive results seen with the use of this laser in the treatment of acne it is reasonable to hypothesize that a similar effect may be seen with the treatment of hidradenitis suppurativa. the specific aim of the study is to determine the efficacy of this device for the treatment of hidradenitis suppurativa as it relates to the patient's established treatment. the investigators are trying to determine the efficacy of a laser for the treatment of hidradenitis suppurativa. patients will: * be examined and interviewed * have photographs taken of the treatment site * have a 4mm punch biopsy performed * have wound culture swabs performed

Eligibility criteria:
inclusion criteria: * age equal to or greater than 18 years * general good health and willingness to participate and ability to comply with the study protocol * biopsy proven hidradenitis suppurativa exclusion criteria: * age \< 18 years * pregnancy * hx of collagen vascular or photosensitive disorders * inability to follow-up with treatments

Keywords: hidradenitis supperativa
effect of oral supplementation with curcumin (turmeric) in patients with proteinuric chronic kidney disease

Conditions: Proteinuria

Summary: the purpose of this study is to determine if the oral supplementation with curcumin reduces proteinuria in patients with chronic kidney disease regardless the ethiology.

curcumin is a potent antioxidant found in extracts of the rhizome of the plant curcuma longa l. different studies have demonstrated that curcumin has potent biological activity and therefore is an effective therapeutic agent for the treatment of various ailments. this compound acts as a bifunctional antioxidant: ه is capable of reacting directly with highly reactive oxygen species. ه acts indirectly by its ability to induce the expression of various cytoprotective proteins through keap1/nrf2/are pathway. although raas blockade is the cornerstone to prevent the progression of proteinuric nephropathy, a significant number of patients remained with proteinuria and progress to end-stage renal disease. due to the low cost and few side effects of curcumin, this could become an adjuvant treatment of proteinuric nephropathy purposes attenuate the progression of chronic kidney disease.

Eligibility criteria:
inclusion criteria: * diagnosis of proteinuric chronic kidney disease with 1g or more of proteins in a daily recollection. * individuals taking angiotensin ii receptor blocker or ace inhibitors in monotherapy with maximum dose or in combination. exclusion criteria: * hepatic damage. * malignancy. * pregnancy. * peritoneal or hemodialysis. * organ transplantation. * heart failure classification iii or iv (new york heart association). * history of chemotherapy within 2 years prior to screening.
a 2-part study consisting of multiple ascending dose (mad) safety study, and a dose-finding masked study to assess the safety and efficacy of intravitreal (ivt) eye103 in patients with diabetic macular edema (dme) or neovascular age-related macular degeneration (nvamd)

Conditions: Neovascular Age-related Macular Degeneration (NVAMD); Diabetic Macular Edema (DME)

Summary: eye103-101 is a 2-part study assessing safety and preliminary efficacy of eye103 in patients with diabetic macular edema (dme) given as monotherapy or neovascular macular degeneration (nvamd) given in combination with anti-vegf. in the first part, termed the multiple ascending dose (mad) portion of study, the safety of eye103 will be assessed at escalating doses. approximately 12 participants will be entered in this part of the study. in the second part of the study, called the dose finding part two doses of eye103 will be selected and their effectiveness will be compared. approximately 80 participants will be entered in this part of the study.

eye103-101 is a 2-part study assessing safety and preliminary efficacy of eye103 in patients with diabetic macular edema (dme) given as monotherapy or neovascular macular degeneration (nvamd) given in combination with anti-vegf. in the first part, termed the multiple ascending dose (mad) portion of study, the safety of eye103 will be assessed at escalating doses. approximately 12 participants will be entered in this part of the study. in the second part of the study, called the dose finding part two doses of eye103 will be selected and their effectiveness will be compared. approximately 80 participants will be entered in this part of the study.

Eligibility criteria:
inclusion criteria: * be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity * dme patients must be ≥ 18 years of age, nvamd patients must be ≥ 50 years of age * diagnosis of either dme or nvamd. dme patients must be treatment naïve. nvamd patients can be either treatment naïve or treatment experienced. * dme patients must have vision loss in the study eye * nvamd patients can be either treatment-naïve or treatment experienced with vision loss in the study eye exclusion criteria: * be pregnant or breastfeeding * history of cataract surgery and/or minimally invasive glaucoma surgery (migs) within 3 months of screening * yttrium-aluminum garnet (yag) laser capsulotomy within 2 months of screening * any other condition except for dme or nvamd or that could affect interpretation of study assessments

Keywords: neovascular age-related macular degeneration (nvamd) diabetic macular edema (dme) age-related macular degeneration (amd)
the neural code and dynamics of the reading network.

Conditions: Epilepsy; Brain Tumor

Summary: the purpose of this study is to compare organization of normal brain function as detected using functional magnetic resonance imaging (fmri) in normal subjects as opposed to patients with epilepsy or brain tumors, to ascribe precise anatomic labels (including brodmann areas) and functional significance to each region involved in cognitive processes as detected by cortical stimulation mapping (csm) in patients with implanted subdural electrodes (sde) or depth (seeg) electrodes, to describe the locations of these regions in talairach space, for a population of patients without overt structural abnormalities in these regions, to generate a spatial probability map of locations of cortical regions "essential" for these processes, to compare the loci of "crucial" language, visual, motor and cognitive sites as determined by csm with the loci determined by a battery of tasks using fmri for each individual and to use these data in patients undergoing intracranial electro-corticographyto determine the loci of essential, involved and uninvolved brain areas, and use sophisticated mathematical analyses of these intracranial recordings to study information flow between these areas.


Eligibility criteria:
inclusion criteria: * patients with medically refractory epilepsy who are scheduled to undergo or have previously undergone placement of sub-dural electrodes (including depth electrodes) to localize the site of seizure onset and to map the locations of critical language and motor regions * patients with epilepsy, brain tumors or cortically based vascular malformations (cavernous malformations or arterio-venous malformations) with lesions that are/were proximate to crucial brain regions, and who are scheduled to undergo or have previously undergone intra-op mapping of motor, visual or language function, or a wada test, or maybe part of an awake craniotomy. * proficiency in english exclusion criteria: * gross structural abnormalities (large hamartomata, tumors, large vascular malformations, very large diffuse malformations of cortical development) that may have impacted upon the location of critical brain areas. * unable to participate in testing due to impaired cognition or mental retardation. * cardiac pacemakers, intracranial aneurysm clips, or other potentially mobile implanted metallic devices * patients with claustrophobia who cannot undergo an mri scan without sedation

Keywords: seizure
a retrospective study of the relationship between white matter hyperintensities(wmhs) within the cholinergic pathways and the cognition of pd patients after bilateral stn dbs

Conditions: Parkinson's Disease

Summary: to retrospectively investigate the relationship between the cholinergic pathways hyperintensities scale (chips) score and the change of cognitive status of parkinson's disease (pd) patients after bilateral subthalamic nucleus deep brain stimulation (stn dbs).

in this observational study, we will retrospectively analyze 38 pd patients who received bilateral stn dbs in the first affiliated hospital of sun yat-sen university during the year of 2008-2012. all patients will be evaluated by unified parkinson's disease rating scale part iii(updrsiii) before and after operation. mini-mental state examination (mmse), montreal cognitive assessment(moca) in the on medication condition pre-operation and on stimulation on medication condition post-operation. the follow-up time points are one week pre-operation and 6, 12, 24 months post-operation. before operation, white matter hyperintensities（wmhs）in the cholinergic pathways will be determined on a 3.0 tesla mri, using the visual rating scale of cholinergic pathways hyperintensities scale (chips). a correlation analysis will be conducted to investigate the relationship between chips score and the change of cognitive status of pd patients after bilateral stn dbs retrospectively.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of parkinson's disease according to united kingdom parkinson's disease brain bank criteria * experience bilateral stn dbs surgery in the first affiliated hospital, sun yat-sen university, china. * preoperative 3.0 tesla mri scanning. exclusion criteria: * loss to follow-up * participation in other clinical trials

Keywords: subthalamic nucleus deep brain stimulation cognition white matter hyperintensities
effect of urine-guided hydration on acute kidney injury after crs-hipec

Conditions: Cytoreductive Surgery; Hyperthermic Intraperitoneal Chemotherapy; Hydration; Diuresis; Acute Kidney Injury; Postoperative Complications

Summary: acute renal injury (aki) is a common complication after cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (crs-hipec), and is associated with worse outcomes. available evidences show that maintaining intraoperative urine output ≥ 200 ml/h by fluid and furosemide administration may reduce the incidence of aki in patients undergoing cardiopulmonary bypass. the investigators hypothesize that, for patients undergoing crs-hipec, intraoperative urine-volume guided hydration may also reduce the incidence of postoperative aki.

acute renal injury (aki) is a common complication after cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (crs-hipec), and is associated with worse outcomes. studies showed that less intraoperative urine volume was associated with aki. in studies of contrast-associated aki, intraoperative and 4-h postoperative hydration and forced diuresis to achieve urine output ≥ 300 ml/h reduces the incidence of aki by 44%. in patients undergoing cardiac surgery under cardiopulmonary bypass, maintaining intraoperative and 6-h postoperative urine output ≥200 ml/h by fluid and furosemide administration reduces the incidence of aki by 52%. for patients with rhabdomyolysis, it is recommended to maintain urine output at approximately 3 ml/kg/h (200 ml/h) with volume supplementation. we suppose that forced diuresis with simultaneous hydration (balancing urine output with intravenous fluid infusion) may reduce aki after crs-hipec. the purpose of this randomised controlled trial is to investigate whether maintaining urine output at 200 ml/h (3 ml/kg/h) or higher by forced diuresis with simultaneous hydration can reduce the incidence of aki after crs-hipec.

Eligibility criteria:
inclusion criteria: * age ≥18 years; * diagnosed as pseudomyxoma peritonei, scheduled for cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy under general anesthesia; * at least 14 days since the last treatment of chemotherapy, radiotherapy, or immunotherapy; * consent to participate in this study. exclusion criteria: * persistent preoperative atrial fibrillation, or new-onset cardiovascular event (acute coronary syndrome, stroke, or congestive heart failure) in the past 3 months; * requirement of vasopressors to maintain blood pressure before surgery; * known furosemide hypersensitivity; * chronic kidney disease stage 5 or requirement of renal replacement therapy; * other conditions that are considered unsuitable for the study participation.

Keywords: cytoreductive surgery hyperthermic intraperitoneal chemotherapy hydration diuresis acute kidney injury postoperative complications
muscle transplantation in strabismus surgery

Conditions: Strabismus, Noncomitant

Summary: all the patients underwent standard muscle transplantation, where the resected extra stump of lateral or medial rectus muscle was transplanted to the medial or lateral rectus muscle using 6-0 prolene which wasrecessed by a standard recession technique


Eligibility criteria:
inclusion criteria: * patients with esotropia or exotropia of more than 60 prism dioptre exclusion criteria: * muscular paralysis. * high myopia. .dissociated vertical divergence. .accommodative esotropias. * large vertical deviations associated alphabetic syndromes * previous surgeries in either eye